Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
Clinicians should pay more attention to the AEs of gastrointestinal and muscular system during combination therapy, and it is recommended to strengthen pharmaceutical care during clinical application.
Authors
- Wenya Shan (ORCID: https://orcid.org/0000-0002-5915-7251)
- Shasha Wu (ORCID: https://orcid.org/0000-0002-2461-6323)
- Qun Li (ORCID: https://orcid.org/0000-0002-7194-7504)
Institutions
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.3389/fphar.2025.1415701
- Citations
- 3
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 6.02